1. Name Of The Medicinal Product
CoAprovel 150/12.5 mg tablets.
CoAprovel 300/12.5 mg tablets.
2. Qualitative And Quantitative Composition
Each CoAprovel 150/12.5 mg tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Each CoAprovel 300/12.5 mg tablet contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
For excipients, see 6.1.
3. Pharmaceutical Form
Tablet.
CoAprovel 150/12.5 mg: Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
CoAprovel 300/12.5 mg: Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
4. Clinical Particulars
4.1 Therapeutic Indications
Treatment of essential hypertension.
This fixed dose combination is indicated in patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
4.2 Posology And Method Of Administration
CoAprovel can be used once daily, with or without food in patients whose blood pressure is not adequately controlled by irbesartan or hydrochlorothiazide alone.
Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) can be recommended.
When clinically appropriate direct change from monotherapy to the fixed combinations may be considered:
• CoAprovel 150/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
• CoAprovel 300/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoAprovel 150/12.5 mg.
Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended.
When necessary, CoAprovel may be administered with another antihypertensive drug (see 4.5).
Renal impairment: due to the hydrochlorothiazide component, CoAprovel is not recommended for patients with severe renal dysfunction (creatinine clearance < 30 ml/min). Loop diuretics are preferred to thiazides in this population. No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is
Intravascular volume depletion: volume and/or sodium depletion should be corrected prior to administration of CoAprovel.
Hepatic impairment: CoAprovel is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function. No dosage adjustment of CoAprovel is necessary in patients with mild to moderate hepatic impairment (see 4.3).
Elderly patients: no dosage adjustment of CoAprovel is necessary in elderly patients.
Children: safety and efficacy of CoAprovel have not been established in children (< 18 years).
4.3 Contraindications
Second and third trimester of pregnancy (see 4.6).
Lactation (see 4.6).
Hypersensitivity to the active substances, to any of the excipients (see 6.1), or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance).
The following contraindications are associated with hydrochlorothiazide:
• severe renal impairment (creatinine clearance < 30 ml/min),
• refractory hypokalemia, hypercalcaemia,
• severe hepatic impairment, biliary cirrhosis and cholestasis.
4.4 Special Warnings And Precautions For Use
Hypotension - Volume-depleted patients: CoAprovel has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension. Symptomatic hypotension may be expected to occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before initiating therapy with CoAprovel.
Renal artery stenosis - Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin
Renal impairment and kidney transplantation: when CoAprovel is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended. There is no experience regarding the administration of CoAprovel in patients with a recent kidney transplantation. CoAprovel should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see 4.3). Thiazide diuretic-associated azotemia may occur in patients with impaired renal function. No dosage adjustment is necessary in patients with renal impairment whose creatinine clearance is
Hepatic impairment: thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. There is no clinical experience with CoAprovel in patients with hepatic impairment.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Primary aldosteronism: patients with primary aldosteronism generally will not respond to anti-hypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of CoAprovel is not recommended.
Metabolic and endocrine effects: thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during thiazide therapy.
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in CoAprovel, minimal or no effects were reported.
Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.
Electrolyte imbalance: as for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.
Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalemia, hyponatremia, and hypochloremic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.
Although hypokalemia may develop with the use of thiazide diuretics, concurrent therapy with irbesartan may reduce diuretic-induced hypokalemia. The risk of hypokalemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH. Conversely, due to irbesartan component of CoAprovel hyperkalemia might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with CoAprovel (see 4.5).
There is no evidence that irbesartan would reduce or prevent diuretic-induced hyponatremia. Chloride deficit is generally mild and usually does not require treatment.
Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.
Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnaesemia.
Anti-doping test: hydrochlorothiazide contained in this medication could produce a positive analytic result in an anti-doping test.
General: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensinconverting enzyme inhibitors or angiotensin
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.
In the first trimester of pregnancy, CoAprovel is not recommended (see 4.6).
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Other antihypertensive agents: the antihypertensive effect of CoAprovel may be increased with the concomitant use of other antihypertensive agents. Irbesartan and hydrochlorothiazide (at doses up to 300 mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other antihypertensive agents including calcium channel blockers and beta
Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with CoAprovel. Lithium and CoAprovel should be co-administered with caution and careful monitoring of serum lithium levels is recommended.
Medicinal products affecting potassium: the potassium-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium.
Medicinal products affected by serum potassium disturbances: periodic monitoring of serum potassium is recommended when CoAprovel is administered with drugs affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).
Additional information on irbesartan interactions:the pharmacokinetics of digoxin were not altered by co-administration of a 150 mg dose of irbesartan in healthy male volunteers. The pharmacokinetics of irbesartan are not affected by co-administration of hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. Inhibition of the glucuronyl transferase pathway is unlikely to result in clinically significant interactions. In vitro interactions were observed between irbesartan and warfarin, tolbutamide (CYP2C9 substrates) and nifedipine (CYP2C9 inhibitor). However, no significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was co-administered with warfarin in healthy male volunteers. The pharmacokinetics of irbesartan are not affected by co-administration of nifedipine. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetics of irbesartan were not evaluated. Based on in vitro data, no interaction would be expected to occur with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1 or CYP3A4.
Additional information on hydrochlorothiazide interactions: when administered concurrently, the following drugs may interact with thiazide diuretics:
Alcohol, Barbiturates, or Narcotics: potentiation of orthostatic hypotension may occur;
Antidiabetic drugs (oral agents and insulins): dosage adjustment of the antidiabetic drug may be required (see 4.4);
Cholestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins;
Corticosteroids, ACTH: electrolyte depletion, particularly hypokalemia, may be increased;
Digitalis glycosides: thiazide induced hypokalemia or hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias (see 4.4);
Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Pressor amines (e.g. noradrenaline): the effect of pressor amines may be decreased, but not sufficiently to preclude their use;
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide;
Antigout medication: dosage adjustments of antigout medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence of hypersensitivity reactions to allopurinol;
Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements or calcium sparing drugs (e.g. Vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly;
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides. Anticholinergic agents (e.g. atropine, beperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of cytotoxic drugs (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
4.6 Pregnancy And Lactation
Pregnancy: See sections 4.3 and 4.4.
Thiazides cross the placental barrier and appear in cord blood. They may cause decrease placental perfusion, foetal electrolyte disturbances and possibly other reactions that have occurred in the adults. Cases of neonatal thrombocytopenia, or foetal or neonatal jaundice have been reported with maternal thiazide therapy. Since CoAprovel contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.
In the second and third trimesters, substances that act directly on the renin-angiotensin-system can cause foetal or neonatal renal failure, foetal skull hyperplasia and even foetal death, therefore, CoAprovel is contra-indicated in the second and third trimesters of pregnancy. If pregnancy is diagnosed, CoAprovel should be discontinued as soon as possible, skull and renal function should be checked with echography, if, inadvertently, the treatment was taken for a long period.
Lactation: because of the potential adverse effects on the nursing infant, CoAprovel is contraindicated during lactation (see 4.3). It is not known if irbesartan is excreted in human milk. It is excreted in the milk of lactating rats. Thiazides appear in human milk and may inhibit lactation.
4.7 Effects On Ability To Drive And Use Machines
The effect of CoAprovel on ability to drive and use machines has not been studied, but based on its pharmacodynamic properties, CoAprovel is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.
4.8 Undesirable Effects
Undesirable effects in patients receiving CoAprovel are generally mild and transient.
In placebo-controlled trials with the combination of irbesartan and hydrochlorothiazide, discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan/hydrochlorothiazide-treated patients than for placebo-treated patients. The incidence of adverse events was not related to gender, age, race, or dose.
Clinical adverse events, probably or possibly related, or of unknown relationship to therapy, occurring in 1% or more of hypertensive patients treated with various doses (range: 37.5 mg/6.25 mg to 300 mg/25 mg irbesartan/hydrochlorothiazide) in pooled placebo-controlled trials are presented in the following table:
|
% of Patients
|
|
Adverse Event
|
Irbesartan/HCTZ
n=898
|
Placebo
n=236
|
Headache
|
6.6
|
10.2
|
Dizziness
|
5.6
|
3.8
|
Fatigue
|
4.9 *
|
1.7
|
nausea/vomiting
|
1.8
|
0.0
|
abnormal urination
|
1.4
|
0.8
|
* Statistically significant difference between irbesartan/HCTZ and placebo treatment groups.
|
|
|
Other clinical events probably or possibly related, or of uncertain relationship to therapy occurring with a frequency of 0.5% to < 1% and at a slightly increased incidence in irbesartan/hydrochlorothiazide-treated patients than in placebo treatment, include: oedema, sexual dysfunction, diarrhoea, dizziness (orthostatic), flushing, libido changes, tachycardia, swelling of the extremities. None of these events were statistically significantly different between irbesartan/hydrochlorothiazide-treated and placebo-treated patients.
In rare cases, patients treated with irbesartan/hydrochlorothiazide had changes in laboratory test parameters known to be associated with thiazide therapy (increases in BUN, creatinine and creatinine kinase, decreases in serum potassium and sodium). These changes were rarely clinically significant.
Post marketing experience: as with other angiotensin-II receptor antagonists, rare cases of hypersensitivity reactions (rash, urticaria, angioedema) have been reported. The following have also been reported very rarely with irbesartan/hydrochlorothiazide during post-marketing surveillance: asthenia, diarrhoea, dizziness, dyspepsia, headache, hyperkalemia, myalgia, nausea, tachycardia, liver function abnormalities, including hepatitis, and impaired renal function including isolated cases of renal failure in patients at risk (see 4.4).
Additional information on individual components: other undesirable effects previously reported with one of the individual components may be potential undesirable effects with CoAprovel, even if not observed in clinical trials.
Irbesartan: adverse events (regardless of relationship to drug) occurred with similar frequency in placebo and irbesartan-treated patients, with the exception of headache, musculoskeletal trauma, and flushing. Headache occurred significantly more often in the placebo group. Musculoskeletal trauma of differing types and causes occurred with a significantly higher incidence in the irbesartan group; all reports of musculoskeletal trauma were considered unrelated to irbesartan by the investigators. Flushing occurred in 0.6% of irbesartan patients and in no placebo patients. The occurrence of flushing was not related to dose, was not accompanied by other clinical events, and the relationship with irbesartan therapy is unknown.
The following additional adverse events, regardless of whether attributed to therapy, were reported to occur with a frequency of
No clinically significant changes in laboratory test parameters occurred in controlled clinical trials. Although significant increases in plasma creatine kinase occurred more frequently in irbesartan-treated subjects (1.7% vs. 0.7% in placebo-treated subjects), none of these increases were classified as serious, resulted in drug discontinuation, or were associated with identifiable clinical musculoskeletal events.
Hydrochlorothiazide: adverse events (regardless of relationship to drug) reported with the use of hydrochlorothiazide alone include: anorexia, loss of appetite, gastric irritation, diarrhoea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, sialadenitis, xanthopsia, leucopenia, neutropenia/agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, bone marrow depression, photosensitivity reactions, fever, rash, cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, urticaria, necrotizing angitis (vasculitis, cutaneous vasculitis), anaphylactic reactions, toxic epidermal necrolysis, respiratory distress (including pneumonitis and pulmonary oedema), hyperglycemia, glycosuria, hyperuricemia, electrolyte imbalance (including hyponatremia and hypokalemia), increases in cholesterol and triglycerides, renal dysfunction, interstitial nephritis, muscle spasm, weakness, restlessness, transient blurred vision, light-headedness, postural hypotension, vertigo, paraesthesia, cardiac arrhythmias, sleep disturbances, depression.
4.9 Overdose
No specific information is available on the treatment of overdosage with CoAprovel. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends on the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdosage. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
The most likely manifestations of irbesartan overdosage are expected to be hypotension and tachycardia; bradycardia might also occur.
Overdosage with hydrochlorothiazide is associated with electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdosage are nausea and somnolence. Hypokalemia may result in muscle spasms and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic drugs.
Irbesartan is not removed by haemodialysis. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmaco-therapeutic group: angiotensin
CoAprovel is a combination of an angiotensin
Irbesartan is a potent, orally active, selective angiotensin1 subtype) antagonist. It is expected to block all actions of angiotensin1 receptor, regardless of the source or route of synthesis of angiotensin1) receptors results in increases in plasma renin levels and angiotensin
Hydrochlorothiazide is a thiazide diuretic. The mechanism of antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics. With hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while the action persists for approximately 6
The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges. The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm Hg. The combination of 300 mg irbesartan and 12.5 mg hydrochlorothiazide resulted in an overall placebo-subtracted systolic/diastolic reductions of up to 13.6/11.5 mm Hg.
Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mm Hg in patients with mild-to-moderate hypertension. Peak effects occurred at 3
In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of irbesartan gave an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mm Hg.
The blood pressure lowering effect of irbesartan in combination with hydrochlorothiazide is apparent after the first dose and substantially present within 1
The effect of the combination of irbesartan and hydrochlorothiazide on morbidity and mortality has not been studied. Epidemiological studies have shown that long term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.
There is no difference in response to CoAprovel, regardless of age or gender. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of non-black patients.
5.2 Pharmacokinetic Properties
Concomitant administration of hydrochlorothiazide and irbesartan has no effect on the pharmacokinetics of either drug.
Irbesartan and hydrochlorothiazide are orally active agents and do not require biotransformation for their activity. Following oral administration of CoAprovel, the absolute oral bioavailability is 60
Plasma protein binding of irbesartan is approximately 96%, with negligible binding to cellular blood components. The volume of distribution for irbesartan is 53
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg was observed; the mechanism for this is unknown. The total body and renal clearance are 157max values were also somewhat greater in elderly subjects (
Following oral or intravenous administration of 14C irbesartan, 80In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidneys. At least 61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier, and is excreted in breast milk.
Renal impairment:in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. In patients with creatinine clearance < 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered. Studies have not been performed in patients with severe hepatic impairment.
5.3 Preclinical Safety Data
Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months. There were no toxicological findings observed of relevance to human therapeutic use.
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two drugs alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed):
• kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;
• slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit);
• stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day. These lesions were not observed in macaques;
• decreases in serum potassium due to hydrochlorothiazide and partly prevented when hydrochlorothiazide was given in combination with irbesartan.
Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan (blockade of angiotensin
No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at doses that produced maternal toxicity. The effects of the irbesartan/hydrochlorothiazide combination on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone. However, another angiotensin
There was no evidence of mutagenicity or clastogenicity with the irbesartan/hydrochlorothiazide combination. The carcinogenic potential of irbesartan and hydrochlorothiazide in combination has not been evaluated in animal studies.
Irbesartan: there was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In preclinical safety studies, high doses of irbesartan (
There was no evidence of mutagenicity, clastogenicity or carcinogenicity.
Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.
Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica, pregelatinised maize starch, red and yellow ferric oxides (E172).
6.2 Incompatibilities
Not applicable.
6.3 Shelf Life
2 years.
6.4 Special Precautions For Storage
Do not store above 30°C.
Store in the original package.
6.5 Nature And Contents Of Container
CoAprovel tablets are packaged in cartons containing 28 tablets in PVC/PVDC/aluminium blisters.
6.6 Special Precautions For Disposal And Other Handling
No special requirements.
7. Marketing Authorisation Holder
SANOFI PHARMA BRISTOL-MYERS SQUIBB SNC
174 avenue de France
F-75013 Paris - France
8. Marketing Authorisation Number(S)
CoAprovel 150/12.5 mg: EU/1/98/086/001
CoAprovel 300/12.5 mg: EU/1/98/086/004
9. Date Of First Authorisation/Renewal Of The Authorisation
15th October 1998
10. Date Of Revision Of The Text
23rd April 2001
Legal Category: POM
